SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+25.14%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$178M
AUM Growth
+$178M
(+9%)
Cap. Flow
+$8.85M
Cap. Flow
% of AUM
4.96%
Top 10 Holdings %
Top 10 Hldgs %
33.95%
Holding
106
New
24
Increased
27
Reduced
29
Closed
17
Top Buys
| 1 |
Aclaris Therapeutics
ACRS
|
$8.49M |
| 2 |
RACB
Research Alliance Corp. II Class A Common Stock
RACB
|
$5.13M |
| 3 |
Merus
MRUS
|
$5.11M |
| 4 |
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
|
$4.01M |
| 5 |
Aldeyra Therapeutics
ALDX
|
$3.82M |
Top Sells
| 1 |
Vericel Corp
VCEL
|
$8.84M |
| 2 |
ESSA Pharma
EPIX
|
$7.25M |
| 3 |
Sutro Biopharma
STRO
|
$4.02M |
| 4 |
Delcath Systems
DCTH
|
$3.87M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$2.57M |
Sector Composition
| 1 | Healthcare | 88.22% |
| 2 | Financials | 2.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Larimar Therapeutics
LRMR
$337M
| $2.8M | 1.53% |
191,945
-25,258
| -12% | -$369K |
|
|
ADMS
27
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $2.51M | 1.37% |
522,589
+81,634
| +19% | +$392K |
|
28
Ascendis Pharma
ASND
$12.1B
| $2.41M | 1.31% |
18,694
+1,138
| +6% | +$147K |
|
29
MoonLake Immunotherapeutics
MLTX
$3.78B
| $2.33M | 1.27% |
228,485
+13,414
| +6% | +$137K |
|
|
SRRA
30
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $2.32M | 1.27% |
134,681
-319
| -0.2% | -$5.5K |
|
31
Kura Oncology
KURA
$732M
| $2.26M | 1.23% |
80,000
-10,000
| -11% | -$283K |
|
|
32
ESSA Pharma
EPIX
$11.2M
| $2.13M | 1.16% |
73,451
-249,466
| -77% | -$7.25M |
|
33
Seres Therapeutics
MCRB
$162M
| $2.06M | 1.12% |
5,000
+3,750
| +300% | +$1.54M |
|
34
Scholar Rock
SRRK
$3.3B
| $1.84M | 1% |
36,221
+11,221
| +45% | +$568K |
|
|
ONCR
35
DELISTED
Oncorus, Inc.
ONCR
| $1.81M | 0.99% |
+130,000
| New | +$1.81M |
|
|
DCPH
36
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $1.78M | 0.97% |
39,765
+1,145
| +3% | +$51.3K |
|
37
Cyclacel Pharmaceuticals
CYCC
$17.2M
| $1.78M | 0.97% |
+69
| New | +$1.78M |
|
38
Evogene
EVGN
$10.8M
| $1.76M | 0.96% |
35,000
-25,000
| -42% | -$1.26M |
|
|
ODT
39
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $1.71M | 0.93% |
+500,000
| New | +$1.71M |
|
40
Arvinas
ARVN
$580M
| $1.66M | 0.9% |
25,071
-29,929
| -54% | -$1.98M |
|
41
Vertex Pharmaceuticals
VRTX
$102B
| $1.61M | 0.88% |
7,500
+2,500
| +50% | +$537K |
|
|
TPTX
42
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $1.58M | 0.86% |
16,741
+610
| +4% | +$57.7K |
|
43
Guardant Health
GH
$8.11B
| $1.56M | 0.85% |
10,192
-8,633
| -46% | -$1.32M |
|
44
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $1.46M | 0.8% |
+100,000
| New | +$1.46M |
|
45
Fulcrum Therapeutics
FULC
$353M
| $1.43M | 0.78% |
121,302
+105,093
| +648% | +$1.24M |
|
46
Biogen
BIIB
$20.8B
| $1.4M | 0.76% |
5,000
+2,000
| +67% | +$560K |
|
|
ARNA
47
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.39M | 0.76% |
20,000
| – | – |
|
48
PolyPid
PYPD
$54.4M
| $1.37M | 0.75% |
+4,994
| New | +$1.37M |
|
49
KalVista Pharmaceuticals
KALV
$713M
| $1.29M | 0.7% |
+50,000
| New | +$1.29M |
|
50
89bio
ETNB
$1.37B
| $1.18M | 0.65% |
50,007
+6,000
| +14% | +$142K |
|